INSTA-MDNCT05644301
INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jan 2023 to Sep 21, 2023
- Site details revised at 3 of 3 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change in depressive symptom severity (HDRS-17)
Timeframe: T0 -> T6 (12 weeks)
Remission rate of depression (HDRS-17)
Timeframe: T0 -> T6 (12 weeks)
Secondary (10)
Change in depressive symptom severity (IDS-30SR)
Response rate of depressive symptoms (HDRS-17)
Change in night-time sleep (PSQI)
Change in anxiety (STAI)
Change in core assessment of psychomotor change (CORE)
Show 5 moreShow less
Depressive symptom profiles (IDS-SR)
Therapy compliance (MARS)
Adverse effects
Metabolic blood markers
Other metabolic measures
Arms and interventions
High Sensitive C-reactive Protein (hs-CRP) < 3mg/L: Minocyclin + Treatment As Usual (TAU)Active comparator
High Sensitive C-reactive Protein (hs-CRP) < 3mg/L: Celecoxib + Treatment As Usual (TAU)Active comparator
High Sensitive C-reactive Protein (hs-CRP) < 3mg/L: Placebo + Treatment As Usual (TAU)Placebo comparator
High Sensitive C-reactive Protein (hs-CRP) > 3mg/L: Minocyclin + Treatment As Usual (TAU)Active comparator
High Sensitive C-reactive Protein (hs-CRP) > 3mg/L: Celecoxib + Treatment As Usual (TAU)Active comparator
High Sensitive C-reactive Protein (hs-CRP) > 3mg/L: Placebo + Treatment As Usual (TAU)Placebo comparator
Drugs: Celecoxib, Minocyclin, Placebo
Sites
3 sites in 1 country